NASDAQ:EDSA Edesa Biotech (EDSA) Stock Price, News & Analysis $5.67 +0.46 (+8.77%) Closing price 03:59 PM EasternExtended Trading$5.78 +0.11 (+1.98%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Edesa Biotech Stock (NASDAQ:EDSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Edesa Biotech alerts:Sign Up Key Stats Today's Range$5.05▼$6.2650-Day Range$4.94▼$18.2752-Week Range$0.72▼$20.32Volume500,217 shsAverage Volume2.68 million shsMarket Capitalization$50.39 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview Edesa Biotech, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology. Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials. In parallel, the company is developing therapeutic vaccine constructs to address oncoviruses and tumor-associated antigens, as well as prophylactic immunizations for broader viral threats. Edesa’s integrated research facilities in Cambridge, Massachusetts support discovery, preclinical evaluation and process development in collaboration with academic and contract manufacturing partners. Headquartered in Cambridge, Edesa Biotech was founded by a team of immunologists and industry veterans. The company serves global markets through strategic alliances in North America, Europe and Asia. Under the leadership of CEO Steven M. Powell, PhD, Edesa is positioned to advance its pipeline toward late-stage clinical trials and to establish a differentiated platform for both infectious disease prevention and cancer immunotherapy.AI Generated. May Contain Errors. Read More Edesa Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreEDSA MarketRank™: Edesa Biotech scored higher than 26% of companies evaluated by MarketBeat, and ranked 697th out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingEdesa Biotech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Downside RiskEdesa Biotech has a consensus price target of $5.00, representing about 11.8% downside from its current price of $5.67.Amount of Analyst CoverageEdesa Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Edesa Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Edesa Biotech are expected to grow in the coming year, from ($1.57) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edesa Biotech is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Edesa Biotech is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEdesa Biotech has a P/B Ratio of 12.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edesa Biotech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.55% of the float of Edesa Biotech has been sold short.Short Interest Ratio / Days to CoverEdesa Biotech has a short interest ratio ("days to cover") of 0.57, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edesa Biotech has recently increased by 9.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdesa Biotech does not currently pay a dividend.Dividend GrowthEdesa Biotech does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.25 News SentimentEdesa Biotech has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Edesa Biotech this week, compared to 3 articles on an average week.Search Interest12 people have searched for EDSA on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Edesa Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders24.40% of the stock of Edesa Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions5.50% of the stock of Edesa Biotech is held by institutions.Read more about Edesa Biotech's insider trading history. Receive EDSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edesa Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EDSA Stock News HeadlinesEdesa Biotech, Inc. Announces $3.5 Million PIPE Financing to Advance Clinical ProgramsJune 11 at 9:31 AM | quiverquant.comQEdesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused InvestorsJune 11 at 9:15 AM | globenewswire.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.June 11 at 1:00 AM | Weiss Ratings (Ad)Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney InjuryJune 5, 2026 | financialpost.comFEdesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury and Respiratory Distress at ERA CongressJune 5, 2026 | quiverquant.comQEdesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney InjuryJune 5, 2026 | globenewswire.comEDSA: Preparing for mid-2026 start to phase 2 vitiligo trialMay 22, 2026 | msn.comEDSA stock soars more than 700% so far this year: Wall Street eyes further upside in run up to acute kidney injury data revealMay 19, 2026 | msn.comSee More Headlines EDSA Stock Analysis - Frequently Asked Questions How have EDSA shares performed this year? Edesa Biotech's stock was trading at $1.42 on January 1st, 2026. Since then, EDSA stock has increased by 299.1% and is now trading at $5.6670. How were Edesa Biotech's earnings last quarter? Edesa Biotech, Inc. (NASDAQ:EDSA) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.25. When did Edesa Biotech's stock split? Edesa Biotech shares reverse split on Wednesday, October 11th 2023.The 1-7 reverse split was announced on Tuesday, October 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. Who are Edesa Biotech's major shareholders? Top institutional investors of Edesa Biotech include Perceptive Advisors LLC (6.34%). Insiders that own company stock include Pardeep Nijhawan and Michael J Brooks. View institutional ownership trends. How do I buy shares of Edesa Biotech? Shares of EDSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edesa Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edesa Biotech investors own include Pfizer (PFE), Ford Motor (F), Moderna (MRNA), Occidental Petroleum (OXY), Plug Power (PLUG), Advanced Micro Devices (AMD) and NVIDIA (NVDA). Company Calendar Last Earnings5/14/2026Today6/11/2026Next Earnings (Estimated)8/14/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 10 days, EDSA's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EDSA CIK1540159 Webwww.edesabiotech.com Phone(289) 800-9600Fax805-488-2889Employees20Year Founded2015Price Target and Rating Average Price Target for Edesa Biotech$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside-11.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.19 million Net MarginsN/A Pretax MarginN/A Return on Equity-286.52% Return on Assets-75.36% Debt Debt-to-Equity RatioN/A Current Ratio4.76 Quick Ratio4.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book12.59Miscellaneous Outstanding Shares8,892,000Free Float6,722,000Market Cap$50.39 million OptionableNot Optionable Beta1.03 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:EDSA) was last updated on 6/11/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
